Send to

Choose Destination
J Proteome Res. 2017 May 5;16(5):1890-1899. doi: 10.1021/acs.jproteome.6b00980. Epub 2017 Apr 17.

Screening and Validation of Novel Biomarkers in Osteoarticular Pathologies by Comprehensive Combination of Protein Array Technologies.

Author information

Proteomics Group-PBR2-ProteoRed/ISCIII, Rheumatology Division, Instituto de Investigación Biomédica de A Coruña (INIBIC/CHUAC/Sergas/UDC) , 15001 A Coruña, Spain.
Affinity Proteomics, Science for Life Laboratory, School of Biotechnology, Royal Institute of Technology (KTH) , SE-17165 Stockholm, Sweden.


Osteoarthritis (OA) is one of the most prevalent articular diseases. The identification of proteins closely associated with the diagnosis, progression, prognosis, and treatment response is dramatically required for this pathology. In this work, differential serum protein profiles have been identified in OA and rheumatoid arthritis (RA) by antibody arrays containing 151 antibodies against 121 antigens in a cohort of 36 samples. Then the identified differential serum protein profiles have been validated in a larger cohort of 282 samples. The overall immunoreactivity is higher in the pathological situations in comparison with the controls. Several proteins have been identified as biomarker candidates for OA and RA. Most of these biomarker candidates are proteins related to inflammatory response, lipid metabolism, or bone and extracellular matrix formation, degradation, or remodeling.


antibody arrays; biomarkers; contact printing; noncontact printing; osteoarthritis; rheumatoid arthritis; serum protein profiles

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center